Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma

Documenti analoghi

• Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS
  di: Nasheed M. Hossain, et al.
  Pubblicazione: (2025)
• Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma
  di: Suguru Morimoto, et al.
  Pubblicazione: (2025)
• Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia
  di: Catherine Aftandilian, et al.
  Pubblicazione: (2024)
• Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma
  di: John Sharp, et al.
  Pubblicazione: (2025)
• Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults
  di: Mustafa Wasifuddin, et al.
  Pubblicazione: (2024)